GlassScriptPhysician profile
Beth T Wiedeman
NPI 1295797462
$3,514.45
in general payments reported to CMS, 2019-2025
35 companies · $972 in 2025
The $972 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $53.01 · 2022: $192 · 2023: $1,051 · 2024: $1,083 · 2025: $972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,105.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $644.07 | 2022-2025 | Vraylar, Ubrelvy, Synthroid |
| Pfizer INC. | $322.13 | 2022-2025 | |
| Lilly USA, LLC | $318.15 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $286.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $177.47 | 2022-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Astellas Pharma US INC | $174.15 | 2019-2025 | Veozah |
| Exact Sciences Corporation | $155.41 | 2023-2025 | Cologuard Collection Kit |
| Shield Therapeutics INC | $154.98 | 2023-2024 | Accrufer |
| Otsuka America Pharmaceutical, INC. | $134.10 | 2022-2025 | Rexulti |
| Lundbeck LLC | $113.10 | 2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $103.77 | 2025 | Caplyta |
| Gilead Sciences, INC. | $80.04 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $68.63 | 2019-2023 | Austedo Xr |
| Abbott Laboratories | $67.16 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $66.83 | 2023-2024 | Trintellix, Gattex |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $63.21 | 2023-2025 | Otezla, Repatha, Repatha |
| Insulet Corporation | $60.64 | 2024-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.07 | 2019-2024 | Tradjenta, Synjardy, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $55.06 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $51.30 | 2022-2024 | Gardasil 9, Gardasil |
| Astrazeneca Pharmaceuticals LP | $45.31 | 2024-2025 | Airsupra |
| Novartis Pharmaceuticals Corporation | $40.14 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $36.09 | 2024-2025 | Gemtesa |
| Axsome Therapeutics, INC. | $33.93 | 2023-2025 | Auvelity |
| Madrigal Pharmaceuticals | $26.57 | 2025 | Rezdiffra |
| Dexcom, INC. | $23.42 | 2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $20.68 | 2025 | Korlym |
| Idorsia Pharmaceuticals US INC | $20.19 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $19.57 | 2024 | Voquezna |
| Neurocrine Biosciences, INC. | $19.01 | 2025 | |
| Axonics, INC. | $15.61 | 2023 | Bulkamid |
| Allergan, INC. | $15.30 | 2019 | |
| Genentech USA, INC. | $15.04 | 2020 | |
| Ibsa Pharma INC. | $14.88 | 2020 | |
| Radius Health, INC. | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Wiedeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.